Biomedical Engineering Reference
In-Depth Information
41. Potet F, Petersen CI, Boutaud O et al (2009) Genetic screening in
C. elegans
identifies rho-
GTPase activating protein 6 as novel HERG regulator. J Mol Cell Cardiol 46:257-267
42. Ritchie TJ, Macdonald SJ (2009) The impact of aromatic ring count on compound
developability - are too many aromatic rings a liability in drug design? Drug Discov
Today 14:1011-1020
43. Sanguinetti MC, Mitcheson JS (2005) Predicting drug-hERG channel interactions that cause
acquired long QT syndrome. Trends Pharmacol Sci 26:119-124
44. Singh JN, Kumar S, Berhe AH et al (2007) QT prolongation: paradigm shift in drug
discovery and development. Curr Res Inform Pharm Sci 8:6-12
45. Pollard CE, Abi Gerges N, Bridgland-Taylor MH et al (2010) An introduction to QT interval
prolongation and non-clinical approaches to assessing and reducing risk. Br J Pharmacol
159:12-21
46. Ponte ML, Keller GA, Di Girolamo G (2010) Mechanisms of drug induced QT interval
prolongation. Curr Drug Saf 5:44-53
47. Roden DM (2004) Drug-induced prolongation of
the QT interval. N Engl J Med
350:1013-1022
48. Wysowski DK, Bacsanyi J (1996) Cisapride and fatal arrhythmia. N Engl J Med
335:290-291
49. Shah RR (2005) Drugs, QT interval prolongation and ICH E14: the need to get it right. Drug
Saf 28:115-125
50. Drolet B, Simard C, Roden DM (2004) Unusual effects of a QT-prolonging drug, arsenic
trioxide, on cardiac potassium currents. Circulation 109:26-29
51. Mathie A (2010) Ion channels as novel therapeutic targets in the treatment of pain. J Pharm
Pharmacol 62:1089-1095
52. Stary A, Wacker SJ, Boukharta L et al (2010) Toward a consensus model of the HERG
potassium channel. ChemMedChem 5:455-467
53. Shimizu W, Moss AJ, Wilde AA et al (2009) Genotype-phenotype aspects of type 2 long QT
syndrome. J Am Coll Cardiol 54:2052-2062
54. Chartrand E, Arnold AA, Gravel A et al (2010) Potential role of the membrane in
hERG channel functioning and drug-induced long QT syndrome. Biochim Biophys Acta
1798:1651-1662
55. Larsen AP, Olesen SP, Grunnet M et al (2010) Pharmacological activation of IKr impairs
conduction in guinea pig hearts. J Cardiovasc Electrophysiol 21:923-929
56. Witchel HJ (2010) Emerging trends in ion channel-based assays for predicting the cardiac
safety of drugs. IDrugs 13:90-96
57. Hong HK, Park MH, Lee BH et al (2010) Block of the human ether-a-go-go-related gene
(hERG) K+ channel by the antidepressant desipramine. Biochem Biophys Res Commun
394:536-541
58. Kang J, Chen XL, Wang H et al (2005) Discovery of a small molecule activator of the human
ether-a-go-go-related gene (HERG) cardiac K+ channel. Mol Pharmacol 67:827-836
59. Zhou J, Augelli-Szafran CE, Bradley JA et al (2005) Novel potent human ether-a-go-go-
related gene (hERG) potassium channel enhancers and their in vitro antiarrhythmic activity.
Mol Pharmacol 68:876-884
60. Yang HT, Sun CF, Cui CC et al (2009) HERG-F463L potassium channels linked to long QT
syndrome reduce I(Kr) current by a trafficking-deficient mechanism. Clin Exp Pharmacol
Physiol 36:822-827
61. Thai KM, Windisch A, Stork D et al (2010) The hERG potassium channel and drug trapping:
insight from docking studies with propafenone derivatives. ChemMedChem 5:436-442
62. Yap YG, Camm AJ (1999) Arrhythmogenic mechanisms of non-sedating antihistamines.
Clin Exp Allergy 29(Suppl 3):174-181
63. Rajput SK, Singh JN, Sharma SS (2010) Evaluation of terfenadine and ketoconazole-induced
QT prolongation in conscious telemetered guinea pigs. Pharmacol Rep 62:683-688
